GlassScriptPhysician profile
Robert S Wooten
NPI 1437134020
$19,079.07
in general payments reported to CMS, 2019-2025
43 companies · $4,677 in 2025
The $4,677 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,457 · 2020: $464 · 2021: $939 · 2022: $3,771 · 2023: $3,175 · 2024: $3,596 · 2025: $4,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,290.92 |
| Education | $156.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,498.15 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,495.40 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,426.84 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $1,393.68 | 2019-2025 | Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $802.11 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $677.74 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $623.60 | 2023-2025 | Voquezna |
| Gilead Sciences, INC. | $594.02 | 2019-2025 | Livdelzi |
| Janssen Scientific Affairs, LLC | $590.06 | 2019-2024 | Stelara |
| Qol Medical, LLC | $560.38 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $538.07 | 2019-2025 | |
| Lilly USA, LLC | $510.71 | 2023-2025 | Omvoh, Zepbound |
| Merck Sharp & Dohme LLC | $467.91 | 2019-2024 | Dificid, Zerbaxa |
| E.R. Squibb & Sons, L.L.C. | $452.97 | 2021-2023 | Zeposia |
| Aimmune Therapeutics, INC. | $369.40 | 2024-2025 | Zenpep, Vowst |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $326.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $324.73 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $323.46 | 2019-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $260.91 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $243.09 | 2022-2025 | Dupixent |
| Celgene Corporation | $206.29 | 2022-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $169.81 | 2024-2025 | Iqirvo |
| Daiichi Sankyo INC. | $147.54 | 2021-2024 | Injectafer |
| Evoke Pharma, INC. | $147.00 | 2022 | |
| Genentech, INC. | $142.18 | 2019 | |
| Celltrion USA INC. | $132.22 | 2024-2025 | Zymfentra, Vegzelma |
| Amgen INC. | $129.03 | 2022-2023 | Amjevita, Avsola |
| Ironwood Pharmaceuticals, INC | $116.83 | 2019-2024 | Linzess |
| Ucb, INC. | $67.15 | 2019-2020 | |
| Vivus LLC | $52.09 | 2024-2025 | Pancreaze |
| Micro-Tech Endoscopy USA, INC. | $49.63 | 2020-2024 | Snares, Button |
| Boston Scientific Corporation | $44.50 | 2019-2025 | Axonics |
| Olympus America INC. | $29.20 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $26.55 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.88 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $18.31 | 2021 | |
| Fresenius Kabi USA, LLC | $18.13 | 2024 | Idacio |
| Amag Pharmaceuticals, INC. | $16.14 | 2022 | |
| Mylan Institutional INC. | $15.45 | 2023 | Hulio |
| Medtronic, INC. | $14.44 | 2022 | |
| Intra-Sana Laboratories | $13.85 | 2022 | |
| Shire North American Group INC | $12.47 | 2019 | |
| Alfasigma USA, INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wooten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.